Tyra biosciences reports second quarter 2024 financial results and highlights

- surf301 ph1 initial results and ach ind submission expected in 2h24 - - reported preclinical proof-of-concept with tyra-300 in hch, demonstrating increases in long bone length and binding against the hch altered protein - - ind cleared for tyra-430, an fgfr4/3 biased inhibitor for hcc - - announced chief medical officer transition plan; search for an external candidate underway with guidance from science & technology (s&t) committee of the board, including recent additions dr. susan moran and dr. s. michael rothenberg - - cash, cash equivalents, and marketable securities of $373.8 million at q2 2024 - carlsbad, calif.
TYRA Ratings Summary
TYRA Quant Ranking